CJC-1295 DAC/Ipamorelin Blend Research & Listing Availability
Current CJC-1295 DAC/Ipamorelin Blend vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
Current CJC-1295 DAC/Ipamorelin Blend vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
About CJC-1295 DAC/Ipamorelin Blend
Pre-clinical / research-onlyAlso known as: CJC-1295 with DAC + Ipamorelin · CJC DAC/IPAThis blend combines CJC-1295 with the Drug Affinity Complex (DAC) — a maleimide-propionic-acid linker that covalently tethers the GHRH(1-29) analog to circulating serum albumin — with the selective ghrelin-receptor (GHS-R1a) agonist ipamorelin. The DAC modification, originally developed by ConjuChem, extends CJC-1295's half-life from minutes to roughly 8 days.[1]
CJC-1295 with DAC produces continuous, albumin-mediated GHRH-receptor activation rather than the pulsatile signal seen with the no-DAC variant — boosting baseline IGF-1 substantially but partially abolishing the body's endogenous GH pulse pattern. Adding ipamorelin recruits the parallel GHS-R1a pathway, which appears in pre-clinical work to partially restore a pulsatile pattern on top of the elevated baseline.[2]
No published trial evaluates the DAC/ipamorelin fixed-ratio blend in humans. Evidence is limited to the individual molecules: Teichman et al. (JCEM 2006) characterized CJC-1295's prolonged action in healthy adults,[2] and Raun et al. (Eur J Endocrinol 1998) established ipamorelin's GH-selectivity over ACTH and prolactin.[3] The blend differs clinically from the more widely studied no-DAC/ipamorelin combination by producing far higher baseline IGF-1 elevation.
Regulatory: Neither component is FDA-approved. CJC-1295 and ipamorelin both appear on the FDA 503A "do not compound" interest list (September 2023). Research-only material.
CJC-1295 DAC/Ipamorelin Blend: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how CJC-1295 DAC/Ipamorelin Blend works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
This research-only blend pairs two molecules from different growth-hormone-secretagogue classes — a long-acting GHRH analog and a selective ghrelin-receptor agonist — neither of which is sold as an FDA-approved pharmaceutical and both of which appear on the FDA 503A "do not compound" interest list as of September 2023.[4][5] CJC-1295 with DAC (Drug Affinity Complex) is a 30-amino-acid analog of growth-hormone-releasing hormone (GHRH 1-29) bearing a maleimide-propionic-acid linker that covalently tethers the peptide to circulating serum albumin via a thiol-reactive reaction with albumin's Cys34 residue.[1] That covalent albumin tether extends the functional half-life from minutes (native GHRH) to roughly 8 days, producing continuous low-grade GHRH-receptor activation on anterior-pituitary somatotrophs rather than the native pulsatile signal.[1][2] The biological consequence in healthy adults is a sustained 2–10× elevation of mean serum IGF-1 over weeks, accompanied by partial preservation — not full abolition — of endogenous overnight GH pulses, as demonstrated in Ionescu/Frohman's frequent-sampling characterisation.[6] Ipamorelin is a pentapeptide selective agonist of the ghrelin receptor (GHS-R1a) — the second, parallel signalling axis driving pituitary GH release.[3] Ipamorelin's selectivity is its defining feature: at GH-releasing doses it does not measurably elevate cortisol, ACTH, or prolactin, in contrast to first-generation secretagogues like GHRP-2 and GHRP-6.[3] Plasma half-life is roughly 2 hours, supporting once- or twice-daily subcutaneous dosing. **For the full mechanism and trial picture of each component, see the standalone CJC-1295 DAC and Ipamorelin deep dives — this blend page focuses on what the combination adds.**
Active research areas
- No published RCT of the specific blend ratioNo randomised controlled trial has evaluated the specific CJC-1295 DAC / Ipamorelin fixed-ratio combination in humans — neither for the dose ratios sold by research-peptide suppliers nor for any clinical endpoint. The blend exists because clinicians and biohackers inferred that pairing the two classes should be additive; that inference is mechanistically reasonable but is not anchored to a controlled-trial dataset.[5]
- CJC-1295 DAC standalone evidenceTeichman and colleagues' Phase 1 study established that single subcutaneous doses of CJC-1295 (with DAC) in healthy adults produced sustained 2–10× elevations of serum IGF-1 lasting roughly 6–11 days,[2] and Ionescu and Frohman demonstrated that endogenous overnight GH pulses are preserved — though dampened in amplitude — under continuous DAC-bound GHRH stimulation.[6] The original Jetté hGRF1-29-albumin bioconjugate work characterised the albumin-tethering mechanism that underpins the DAC modification.[1]
- Ipamorelin standalone evidence (GH-secretagogue selectivity)Raun and colleagues' original 1998 characterisation of ipamorelin established its defining feature: a clean GH-releasing signal at doses that do not measurably elevate cortisol, ACTH, or prolactin — a markedly cleaner endocrine profile than GHRP-2 or GHRP-6.[3] No Phase 3 programme has ever advanced ipamorelin in any human therapeutic indication.
- Rationale for combining GHRH analog + GHS classThe Sigalos/Pastuszak Sex Med Rev review of growth-hormone secretagogues summarises the mechanistic case for combining a GHRH analog (which acts on one pituitary signalling axis) with a ghrelin-receptor agonist (which acts on a second, parallel axis), and notes that the resulting GH/IGF-1 response is typically greater than either class alone in pre-clinical work — but cautions that no Phase 2/3 human dataset has confirmed this for the specific DAC + ipamorelin combination.[5]
- Regulatory status: FDA 503A "do not compound" listingIn September 2023 the FDA placed both CJC-1295 and ipamorelin on its 503A Bulks List of substances that should not be compounded by compounding pharmacies due to safety, identity, and characterisation concerns — effectively closing off the prescription-compounding channel that had served the secretagogue market.[4] The remaining supply is therefore research-grade material sold for non-clinical use.
Open questions & leading hypotheses (3)
- Hypothesis: The DAC + ipamorelin blend produces meaningfully greater IGF-1 elevation and downstream body-composition change than CJC-1295 DAC alone.Evidence: Mechanistically the two molecules act on non-overlapping pituitary signalling axes (GHRH receptor vs GHS-R1a), and the broader pre-clinical secretagogue literature supports additivity of these two classes.[5] Counter-evidence: no human study has directly compared DAC + ipamorelin to DAC alone, and the Teichman DAC-monotherapy data already produce 2–10× IGF-1 elevations[2] — leaving little headroom for an additional pulsatile signal to add measurable IGF-1 on top.
- Hypothesis: Adding ipamorelin to CJC-1295 DAC restores a physiologic pulsatile GH-secretion pattern on top of the elevated tonic baseline.Evidence: Ionescu/Frohman showed that endogenous overnight GH pulses persist under continuous DAC-bound GHRH stimulation,[6] and ipamorelin reliably produces sharp GH pulses on injection in pre-clinical and Phase 1 work.[3] Counter-evidence: nobody has measured the combined GH-secretion time-course in humans, so the assertion that the blend produces a more "physiologic" pattern than DAC alone is mechanistically plausible but not directly demonstrated.
- Hypothesis: Chronic IGF-1 elevation at the levels produced by DAC + ipamorelin protocols carries no meaningful tumour-promotion risk in healthy adults.Evidence: No controlled chronic-use cohort of any size exists for the blend or for either component, and the IGF-1 elevations produced are within or modestly above the upper end of the physiologic range.[2][6] Counter-evidence: the broader IGF-1 oncology literature (covered in detail in the IGF-1 LR3 deep dive) flags sustained IGF-1R activation as a permissive factor for established epithelial tumour growth, and the chronic dosing schedules used in community practice have never been characterised for cancer-incidence risk in any prospective cohort.
What community users report
Anecdotal — not controlled-trial evidence
On r/Peptides and r/PeptideAdmin, the CJC-1295 DAC / Ipamorelin blend is typically run at 100–300 µg of each peptide once or twice per day, frequently in 8–12-week courses with a similar off-cycle window, and is most commonly framed as a "GH baseline + pulse" stack aimed at body-composition change, sleep quality, and connective-tissue recovery.[7][8] Reported subjective effects most often cited include deeper sleep within the first 1–2 weeks (consistent with both molecules' established effects on slow-wave sleep architecture in the published literature), slowly-developing fullness/leanness over 4–8 weeks, and occasional water retention or hand/foot tenderness at the higher end of the dose range — the latter consistent with elevated IGF-1's effects on connective tissue. **All community reports are anecdotal and have not been validated in controlled trials.** Importantly, both CJC-1295 and ipamorelin are now on the FDA 503A "do not compound" list,[4] every published Phase 1/2 study cited above tested the individual molecules — not the blend ratio sold by suppliers — and the chronic-use safety profile of the specific blend at community-protocol doses has never been characterised in a controlled setting.
Sources & references (8)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Jetté L et al. hGRF1-29-albumin bioconjugates activate the GHRH receptor and release GH and IGF-I in healthy male volunteers. Endocrinology 2005;146:3052–3058. · PMID: 15817669 link
- [2]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. JCEM 2006;91:799–805. · PMID: 16352683 link
- [3]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552–561. · PMID: 9849822 link
- [4]FDA 503A Bulks List — CJC-1295 and ipamorelin entries, September 2023. link
- [5]Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018;6:45–53. · PMID: 28400207 link
- [6]Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. JCEM 2006;91:4792–4797. · PMID: 17018654 link
- [7]Community report — r/Peptides CJC-1295 DAC / Ipamorelin blend protocol threads (subreddit), accessed May 2026. link
- [8]Community report — r/PeptideAdmin CJC-DAC/IPA dosing and IGF-1 response discussions (subreddit), accessed May 2026. link
CJC-1295 DAC/Ipamorelin Blend Calculator Input Observations
In lifetime CJC-1295 DAC/Ipamorelin Blend calculator inputs, 250mcg is the most frequent entered amount (68 of 394 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (35 of 148 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 250mcg, Daily (7x/wk) is most frequent (6 of 17 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length.
About CJC-1295 DAC/Ipamorelin Blend
This blend combines CJC-1295 with the Drug Affinity Complex (DAC) — a maleimide-propionic-acid linker that covalently tethers the GHRH(1-29) analog to circulating serum albumin — with the selective ghrelin-receptor (GHS-R1a) agonist ipamorelin. The DAC modification, originally developed by ConjuChem, extends CJC-1295's half-life from minutes to roughly 8 days.
CJC-1295 DAC/Ipamorelin Blend is a blend of CJC-1295 DAC and Ipamorelin, so a COA has to confirm each component separately — a single purity figure for the mixture is not enough. Its reported half-life is ~6–8 days (CJC-DAC-driven). Calculator inputs do not establish why a cadence was selected or validate a protocol. Neither component is FDA-approved.
Frequently Asked Questions: CJC-1295 DAC/Ipamorelin Blend
Are current CJC-1295 DAC/Ipamorelin Blend offers available?
Current CJC-1295 DAC/Ipamorelin Blend vial offers are unavailable in this comparison. Research information remains available; this does not establish permanent discontinuation.
What can I check if CJC-1295 DAC/Ipamorelin Blend listings become available?
Check the exact compound, format, labelled quantity, named laboratory, test date, and batch match. Confirm any future listing price, discount terms, and stock directly with the vendor. Catalog COA fields alone are not independent verification.
Does research activity establish current CJC-1295 DAC/Ipamorelin Blend availability?
No. Search interest, calculator entries, historical prices, related compounds, and other formats do not establish current offers in this comparison. Research information and navigation to other compounds remain available.